-
2016's Most Hyped Events: How Did It Work Out For The Stocks?
Thursday, December 22, 2016 - 3:11pm | 530Read More...There's nothing better from a public relations standpoint than whipping the public into a frenzy over a new product or service. Several companies made a big splash this year with big announcements, events and launches. Here's a look at how the stocks performed after the initial hype...
-
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Friday, December 2, 2016 - 11:33am | 333Read More...After agreeing to cover Sarepta Therapeutics Inc (NASDAQ: SRPT)’s controversial Duchenne muscular dystrophy drug Exondys 51, insurer Aetna Inc (NYSE: AET) has released a new clinical policy bulletin describing the conditions under which it deems the drug medically necessary. Aetna now...
-
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
Monday, November 21, 2016 - 2:19pm | 607Read More...Back on October 6, Duchenne Muscular Dystrophy (DMD) treatment advocate Jenn McNary announced on Twitter that Humana Inc (NYSE: HUM) had approved 100 percent coverage for a patient wanting access to Sarepta Therapeutics Inc (NASDAQ: SRPT) muscular dystrophy drug eteplirsen - marketed as EXONDYS...
-
Sarepta's DMD Drug Should Have A Strong Launch, But Long-Term Prospects Uncertain
Thursday, October 27, 2016 - 6:44am | 252Read More...Sarepta Therapeutics Inc’s (NASDAQ: SRPT) first drug, Exondys 51 [eteplirsen] has been approved by the FDA for boys with Duchenne Muscular Dystrophy. Although approval for DMD therapy offers the company significant market opportunity, there are long-term uncertainties, Morgan Stanley...
-
Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51
Monday, October 10, 2016 - 6:44am | 352Read More...Commenting on the U.S. commercial launch of Sarepta Therapeutics Inc’s (NASDAQ: SRPT) Exondys 51, Wedbush’s Heather Behanna said that the initial adoption would likely be rapid although logistical challenges may continue. The analyst maintained an Outperform rating on Sarepta, while...
-
Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen
Friday, October 7, 2016 - 10:23am | 356Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) fell about 5 percent Friday after Anthem Blue Cross said the clinical benefit of treatment for DMD (Duchenne Muscular Dystrophy) with the company's eteplirsen (Exondys 51), including improved motor function, has "not been demonstrated....
-
Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations
Wednesday, October 5, 2016 - 12:27pm | 265Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) and Summit Therapeutics PLC (NASDAQ: SMMT) announced a licensing deal Tuesday. Sarepta earns European commercial rights for Summit’s utophin modulation portfolio for an initial $40 million and up to $522 million in milestones and royalties....
-
Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn't The 'Be All End All'
Thursday, September 29, 2016 - 8:28am | 303Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the commencement of dosing in the Phase III ESSENCE study of SRP-4045 and SRP-4053. “If the trial is successful, it could mean more than doubling of Sarepta’s addressable population in the next few years,” Baird’s Brian P...
-
FDA Commish Says Sarepta's DMD Study Should Be Retracted
Thursday, September 22, 2016 - 9:24am | 333Read More...It looks like Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Eteplirsen may not be out of the woods just yet. A letter from U.S. Food & Drug Administration Commissioner Robert Califf is calling for the drug's latest study to be retracted. The 13-page memo is dated Friday,...
-
When Will The Rally In Sarepta Therapeutics End?
Tuesday, September 20, 2016 - 12:14pm | 462Read More...Over the past few years, Sarepta Therapeutics Inc (NASDAQ: SRPT) has been one of the most volatile issues on Wall Street. It's quest to gain FDA approval for Eteplirsen has been a rollercoaster, which has been reflected in the share price of the issue. The battle for the drug's approval...
-
Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform
Tuesday, September 20, 2016 - 10:24am | 300Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...
-
2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50
Tuesday, September 20, 2016 - 9:57am | 315Read More...Jefferies raised its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) as the din dies down on the euphoria generated by the company receiving accelerated approval for eteplirsen in Duchenne Muscular Dystrophy. That said, the firm is still circumspect and feels 2022, when the full approval...
-
Jefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics
Tuesday, September 20, 2016 - 9:44am | 378Read More...PTC Therapeutics, Inc. (NASDAQ: PTCT) shares are up another 4.2 percent in early Tuesday trading following a big 20.6 percent Monday gain. The big move in PTC shares has been driven by the FDA’s accelerated approval of Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Eteplirsen for treatment...
-
Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
Monday, September 19, 2016 - 1:27pm | 335Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared higher by more than 80 percent Monday and hit a new 52-week high of $56.18. Traders turned uber-bullish on the stock after the U.S. Food and Drug Administration granted an accelerated approval for its Duchenne Muscular Dystrophy (DMD) drug...
-
Oppenheimer Raises Sarepta's Target From $60 To $76
Monday, September 19, 2016 - 11:08am | 197Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) have nearly doubled Monday, up 87 percent after the U.S. Food And Drug Administration accelerated approval for its Duchenne Muscular Dystrophy (DMD) drug, Eteplirsen. The drug is the first of its kind to fight this rare disease, which typically...
